Prevalence of human papillomavirus in 5,072 consecutive cervical SurePath samples evaluated with the Roche cobas HPV real-time PCR assay

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Prevalence of human papillomavirus in 5,072 consecutive cervical SurePath samples evaluated with the Roche cobas HPV real-time PCR assay. / Preisler, Sarah; Rebolj, Matejka; Untermann, Anette; Ejegod, Ditte Møller; Lynge, Elsebeth; Rygaard, Carsten; Bonde, Jesper.

In: P L o S One, Vol. 8, No. 3, 22.03.2013, p. e59765.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Preisler, S, Rebolj, M, Untermann, A, Ejegod, DM, Lynge, E, Rygaard, C & Bonde, J 2013, 'Prevalence of human papillomavirus in 5,072 consecutive cervical SurePath samples evaluated with the Roche cobas HPV real-time PCR assay', P L o S One, vol. 8, no. 3, pp. e59765. https://doi.org/10.1371/journal.pone.0059765

APA

Preisler, S., Rebolj, M., Untermann, A., Ejegod, D. M., Lynge, E., Rygaard, C., & Bonde, J. (2013). Prevalence of human papillomavirus in 5,072 consecutive cervical SurePath samples evaluated with the Roche cobas HPV real-time PCR assay. P L o S One, 8(3), e59765. https://doi.org/10.1371/journal.pone.0059765

Vancouver

Preisler S, Rebolj M, Untermann A, Ejegod DM, Lynge E, Rygaard C et al. Prevalence of human papillomavirus in 5,072 consecutive cervical SurePath samples evaluated with the Roche cobas HPV real-time PCR assay. P L o S One. 2013 Mar 22;8(3):e59765. https://doi.org/10.1371/journal.pone.0059765

Author

Preisler, Sarah ; Rebolj, Matejka ; Untermann, Anette ; Ejegod, Ditte Møller ; Lynge, Elsebeth ; Rygaard, Carsten ; Bonde, Jesper. / Prevalence of human papillomavirus in 5,072 consecutive cervical SurePath samples evaluated with the Roche cobas HPV real-time PCR assay. In: P L o S One. 2013 ; Vol. 8, No. 3. pp. e59765.

Bibtex

@article{c713014e3d1f4bc98046f1bead16b505,
title = "Prevalence of human papillomavirus in 5,072 consecutive cervical SurePath samples evaluated with the Roche cobas HPV real-time PCR assay",
abstract = "New commercially available Human Papillomavirus (HPV) assays need to be evaluated in a variety of cervical screening settings. Cobas HPV Test (cobas) is a real-time PCR-based assay allowing for separate detection of HPV genotypes 16 and 18 and a bulk of 12 other high-risk genotypes. The aim of the present study, Horizon, was to assess the prevalence of high-risk HPV infections in an area with a high background risk of cervical cancer, where women aged 23-65 years are targeted for cervical screening. We collected 6,258 consecutive cervical samples from the largest cervical screening laboratory in Denmark serving the whole of Copenhagen. All samples were stored in SurePath media. In total, 5,072 samples were tested with cobas, Hybrid Capture 2 High Risk HPV DNA test (HC2) and liquid-based cytology. Of these, 27{\%} tested positive on cobas. This proportion decreased by age, being 43{\%} in women aged 23-29 years and 10{\%} in women aged 60-65 years. HC2 assay was positive in 20{\%} of samples, and cytology was abnormal (≥ atypical squamous cells of undetermined significance) for 7{\%} samples. When only samples without recent abnormalities were taken into account, 24{\%} tested positive on cobas, 19{\%} on HC2, and 5{\%} had abnormal cytology. The proportion of positive cobas samples was higher than in the ATHENA trial. The age-standardized cobas positivity vs. cytology abnormality was 3.9 in our study and 1.7 in ATHENA. If in Copenhagen the presently used cytology would be replaced by cobas in women above age 30 years, an extra 11{\%} of women would based on historical data be expected to have a positive cobas test without an underlying cervical intraepithelial lesion grade 3 or worse. Countries with a high prevalence of HPV infections should therefore proceed to primary HPV-based cervical screening with caution.",
author = "Sarah Preisler and Matejka Rebolj and Anette Untermann and Ejegod, {Ditte M{\o}ller} and Elsebeth Lynge and Carsten Rygaard and Jesper Bonde",
year = "2013",
month = "3",
day = "22",
doi = "10.1371/journal.pone.0059765",
language = "English",
volume = "8",
pages = "e59765",
journal = "P L o S One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "3",

}

RIS

TY - JOUR

T1 - Prevalence of human papillomavirus in 5,072 consecutive cervical SurePath samples evaluated with the Roche cobas HPV real-time PCR assay

AU - Preisler, Sarah

AU - Rebolj, Matejka

AU - Untermann, Anette

AU - Ejegod, Ditte Møller

AU - Lynge, Elsebeth

AU - Rygaard, Carsten

AU - Bonde, Jesper

PY - 2013/3/22

Y1 - 2013/3/22

N2 - New commercially available Human Papillomavirus (HPV) assays need to be evaluated in a variety of cervical screening settings. Cobas HPV Test (cobas) is a real-time PCR-based assay allowing for separate detection of HPV genotypes 16 and 18 and a bulk of 12 other high-risk genotypes. The aim of the present study, Horizon, was to assess the prevalence of high-risk HPV infections in an area with a high background risk of cervical cancer, where women aged 23-65 years are targeted for cervical screening. We collected 6,258 consecutive cervical samples from the largest cervical screening laboratory in Denmark serving the whole of Copenhagen. All samples were stored in SurePath media. In total, 5,072 samples were tested with cobas, Hybrid Capture 2 High Risk HPV DNA test (HC2) and liquid-based cytology. Of these, 27% tested positive on cobas. This proportion decreased by age, being 43% in women aged 23-29 years and 10% in women aged 60-65 years. HC2 assay was positive in 20% of samples, and cytology was abnormal (≥ atypical squamous cells of undetermined significance) for 7% samples. When only samples without recent abnormalities were taken into account, 24% tested positive on cobas, 19% on HC2, and 5% had abnormal cytology. The proportion of positive cobas samples was higher than in the ATHENA trial. The age-standardized cobas positivity vs. cytology abnormality was 3.9 in our study and 1.7 in ATHENA. If in Copenhagen the presently used cytology would be replaced by cobas in women above age 30 years, an extra 11% of women would based on historical data be expected to have a positive cobas test without an underlying cervical intraepithelial lesion grade 3 or worse. Countries with a high prevalence of HPV infections should therefore proceed to primary HPV-based cervical screening with caution.

AB - New commercially available Human Papillomavirus (HPV) assays need to be evaluated in a variety of cervical screening settings. Cobas HPV Test (cobas) is a real-time PCR-based assay allowing for separate detection of HPV genotypes 16 and 18 and a bulk of 12 other high-risk genotypes. The aim of the present study, Horizon, was to assess the prevalence of high-risk HPV infections in an area with a high background risk of cervical cancer, where women aged 23-65 years are targeted for cervical screening. We collected 6,258 consecutive cervical samples from the largest cervical screening laboratory in Denmark serving the whole of Copenhagen. All samples were stored in SurePath media. In total, 5,072 samples were tested with cobas, Hybrid Capture 2 High Risk HPV DNA test (HC2) and liquid-based cytology. Of these, 27% tested positive on cobas. This proportion decreased by age, being 43% in women aged 23-29 years and 10% in women aged 60-65 years. HC2 assay was positive in 20% of samples, and cytology was abnormal (≥ atypical squamous cells of undetermined significance) for 7% samples. When only samples without recent abnormalities were taken into account, 24% tested positive on cobas, 19% on HC2, and 5% had abnormal cytology. The proportion of positive cobas samples was higher than in the ATHENA trial. The age-standardized cobas positivity vs. cytology abnormality was 3.9 in our study and 1.7 in ATHENA. If in Copenhagen the presently used cytology would be replaced by cobas in women above age 30 years, an extra 11% of women would based on historical data be expected to have a positive cobas test without an underlying cervical intraepithelial lesion grade 3 or worse. Countries with a high prevalence of HPV infections should therefore proceed to primary HPV-based cervical screening with caution.

U2 - 10.1371/journal.pone.0059765

DO - 10.1371/journal.pone.0059765

M3 - Journal article

C2 - 23533648

VL - 8

SP - e59765

JO - P L o S One

JF - P L o S One

SN - 1932-6203

IS - 3

ER -

ID: 45878238